This Pharma Stock Keeps Earning My Money, Here’s Why

3 days ago 3

Quick Read

Eli Lilly (LLY) earns a bargain standing with Q1 gross up 55.5% and banal down 10.21% year-to-date.
Lilly sits astatine the halfway of the GLP-1 therapeutic displacement with Mounjaro and Zepbound driving 65% measurement growth.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Eli Lilly wasn't 1 of them. Get them present FREE.

I support buying Eli Lilly (NYSE:LLY), and the latest 4th conscionable made it harder to stop. This is simply a confession of conviction. I person been adding done each dip successful 2026, and the astir caller net study told maine the thesis is accelerating.

What pulls maine backmost to the bargain fastener is simple. Lilly sits astatine the halfway of the largest therapeutic displacement successful modern medicine, the GLP-1 build-out for diabetes and obesity, and it is the lone institution with a metabolic franchise this deep, this fast-growing, and this defensible.

When CEO David Ricks said "2026 is disconnected to a beardown start" and that Foundayo "will meaningfully grow the fig of radical who tin payment from GLP-1s," I work that arsenic the adjacent limb of compounding starting.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Eli Lilly wasn't 1 of them. Get them present FREE.

The information down the condemnation

Reason 1 is the maturation engine. Q1 2026 gross came successful astatine $19.80 billion, up 55.5% twelvemonth implicit year, with non-GAAP EPS of $8.55 against a $6.79 consensus.

Mounjaro printed $8.662 billion, up 125%, and Zepbound delivered $4.160 billion, up 80%. Management raised full-year guidance to $82 cardinal to $85 cardinal successful gross and $35.5 to $37 successful non-GAAP EPS. Companies this size bash not turn this accelerated by accident.

An infographic titled 'This Stock Keeps Earning My Money' for Eli Lilly (NYSE: LLY), highlighting condemnation successful its GLP-1 build-out. It is divided into 5 sections. Section 1, 'THE GROWTH ENGINE (Q1 2026)', shows Revenue astatine $19.80 Billion (+55.5% YoY, Beat Estimates) and Non-GAAP EPS astatine $8.55 (vs $6.79 Consensus), some depicted with upward trending barroom graphs. It besides lists Mounjaro Revenue astatine $8.662 Billion (+125% YoY) and Zepbound Revenue astatine $4.160 Billion (+80% YoY), on with Raised FY2026 Guidance for Revenue ($82.0B-$85.0B) and Non-GAAP EPS ($35.50-$37.00). Section 2, 'THE DIVIDEND RECORD (COMPOUNDING)', illustrates Quarterly Payouts expanding from $1.30 (2024) to $1.50 (2025) and $1.73 (Q1 2026), and states Annual Dividends accrued from $2.08 (2017) to $6.00 (2025). Section 3, 'PIPELINE & INSIDER CONVICTION', details 'PIPELINE INNOVATION' with Foundayo (FDA-Approved) and mentions Retatrutide, Jaypirca, Ebglyss, Kisunla. Under 'INSIDER SIGNAL', it notes CEO David Ricks bought 38,913 Shares @ $1,044.67 (Feb 9, 2026) and Consistent Director Buying by 4 directors successful Feb, Mar, & Apr 2026. Section 4, 'THE HONEST RISK (PRICING VS. VOLUME)', visually represents a equilibrium scale. 'PRICING HEADWINDS' lists Realized Prices Down 13% (Q1 2026) and Gross Margin Slipped to 82.6%. 'VOLUME GROWTH' shows a 65% Volume Increase. Section 5, 'WHY THE BUY BUTTON STAYS ACTIVE', presents 5-Year Return (+453.87%), 10-Year Return (+1391.89%), Analyst Consensus (Target Price $1,202.17 | 24 BUY, 1 SELL), and YTD Performance (-10.21%). The bottommost of the infographic states 'Current Date: Sunday, May 3, 2026'.

Reason 2 is the dividend record. The quarterly payout climbed from $1.30 successful 2024 to $1.50 crossed 2025 and past $1.73 successful Q1 2026. Annual dividends went from $2.08 successful 2017 to $6 successful 2025. That is the benignant of compounding I privation sitting successful a status relationship for a decade.

Reason 3 is the pipeline and insider conviction. Foundayo, the lone approved GLP-1 pill with nary nutrient oregon h2o restrictions, opens an oral marketplace Ricks pegs astatine "over 1 cardinal radical astir the satellite with obesity and related conditions." Behind it beryllium retatrutide, Jaypirca, Ebglyss, Kisunla, and 4 announced acquisitions. Then connected February 9, 2026, CEO Ricks bought 38,913 shares astatine $1,044.67, alongside much than a twelve different executives. Four directors person kept buying successful February, March, and April 2026. That is the clearest awesome I track.

The honorable hazard

Pricing is the existent concern. Realized prices fell 13% successful Q1, gross borderline slipped to 82.6%, and the Mounjaro NRDL summation successful China compresses planetary economics. Revenue attraction successful 2 products is simply a genuine vulnerability. The crushed it has not changed my thesis is volume.

Read Entire Article